Literature DB >> 12162406

Epidermal growth factor inhibits the growth of TE8 esophageal cancer cells through the activation of STAT1.

Makoto Ichiba1, Yoshiji Miyazaki, Shinji Kitamura, Tatsuya Kiyohara, Yasuhisa Shinomura, Yuji Matsuzawa.   

Abstract

BACKGROUND: Epidermal growth factor receptors (EGFRs) mediate growth signals in a variety of normal and malignant cells. However, the issue of whether the EGF/EGFR system contributes to the progression of esophageal cancer cells remains controversial. The aim of the present study was to determine the role of EGFR in the growth of esophageal cancer cell lines.
METHODS: Three esophageal cancer cell lines, TE1, TE2, and TE8, were stimulated with EGF, and cellular growth was then evaluated by cell number. The activation of signal transducers and activators of transcription (STATs) and the expression of the cyclin-dependent kinase (CDK) inhibitor p21/WAF1 were determined by an electromobility shift assay and Northern blot analysis, respectively.
RESULTS: EGF inhibited the growth of TE8 cells, while no significant effects were observed for TE1 and TE2 cells. The treatment of TE8 cells with EGF induced the activation of STAT1 and STAT3, followed by the expression of p21/WAF1. The introduction of a dominant-negative STAT1 construct into TE8 cells abolished not only growth inhibition but also p21/WAF1 induction by EGF.
CONCLUSIONS: The findings herein suggest that EGF inhibits the growth of some esophageal cancer cells that overexpress EGFR and that the activation of STAT1 constitutes a critical event which is required for the inhibition of growth by EGF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12162406     DOI: 10.1007/s005350200077

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  8 in total

1.  STAT3 Inhibition Induces Apoptosis in Cancer Cells Independent of STAT1 or STAT2.

Authors:  Adetola Shodeinde; Kalyani Ginjupalli; H Dan Lewis; Sheraz Riaz; Beverly E Barton
Journal:  J Mol Biochem       Date:  2013-02-20

2.  Predictive value of EGF and uPAR for chemoradiotherapy response and survival in patients with esophageal squamous cell carcinoma.

Authors:  Xi Chen; Hui Wei; Dong Qian; Yuwen Wang; Yong Guan; Puchun Er; Yongchun Song; Ningbo Liu; Jun Wang; Lujun Zhao; Zhiyong Yuan; Ping Wang; Qingsong Pang; Wencheng Zhang
Journal:  Ann Transl Med       Date:  2020-09

3.  Effects of epidermal growth factor and its signal transduction inhibitors on apoptosis in human colorectal cancer cells.

Authors:  Jane C J Chao; Wen Li Peng; Sheng-Hsuan Chen
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

4.  Activation of Toll‐like receptor 9 inhibits lipopolysaccharide‐induced receptor activator of nuclear factor kappa‐ B ligand expression in rat B lymphocytes.

Authors:  Xiaoqian Yu; Jiang Lin; Qing Yu; Toshihisa Kawai; Martin A Taubman; Xiaozhe Han
Journal:  Microbiol Immunol       Date:  2014-01       Impact factor: 1.955

5.  Association of esophageal candidiasis and squamous cell carcinoma.

Authors:  C E Delsing; C P Bleeker-Rovers; F L van de Veerdonk; J Tol; J W M van der Meer; B J Kullberg; M G Netea
Journal:  Med Mycol Case Rep       Date:  2012-03-01

6.  The clinical and biological significance of STAT1 in esophageal squamous cell carcinoma.

Authors:  Ying Zhang; Ommoleila Molavi; Min Su; Raymond Lai
Journal:  BMC Cancer       Date:  2014-10-29       Impact factor: 4.430

7.  Prognostic significance and function of the vacuolar H+-ATPase subunit V1E1 in esophageal squamous cell carcinoma.

Authors:  Sung Wook Son; Seok-Hyung Kim; Eun-Yi Moon; Dong-Hoon Kim; Suhkneung Pyo; Sung Hee Um
Journal:  Oncotarget       Date:  2016-08-02

8.  NRD1, which encodes nardilysin protein, promotes esophageal cancer cell invasion through induction of MMP2 and MMP3 expression.

Authors:  Naohiro Uraoka; Naohide Oue; Naoya Sakamoto; Kazuhiro Sentani; Htoo Zarni Oo; Yutaka Naito; Tsuyoshi Noguchi; Wataru Yasui
Journal:  Cancer Sci       Date:  2013-11-29       Impact factor: 6.716

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.